Anna Chan

No ORCID on file · 3 papers in corpus · active 2023-2025

Study types

  • article 3

Condition tags

  • endometriosis 3
article 2025
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain
AJOG global reports ·doi:10.1016/j.xagr.2025.100584

BACKGROUND: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…

article 2024
LONG-TERM ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS + 12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY
·doi:10.1016/j.fertnstert.2024.07.557
article 2023
LONG-TERM THERAPY OF ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY
·doi:10.1016/j.fertnstert.2023.08.206